Thymus Neuroendocrine Carcinoma — Trials

Thymus Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Novartis Pharmaceuticals
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07006727	Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors	recruiting	Phase 1	116	Novartis PharmaceuticalsINDUSTRY	4	Sep 22, 2026	clinicaltrials

Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials